Impact of Body Mass Index on Surgical and Oncological Outcomes in Laparoscopic Total Mesorectal Excision for Locally Advanced Rectal Cancer after Neoadjuvant 5-Fluorouracil-Based Chemoradiotherapy
Table 1
Clinicopathological characteristics between nonobese and obese groups in locally advanced rectal cancer patients following nCRT.
Characteristics
BMI < 25 ()
BMI ≥ 25 ()
value
Sex
0.085
Male
157 (63.1)
47 (74.6)
Female
92 (36.9)
16 (25.4)
Age (years)
54.9 ± 12.0
54.7 ± 9.1
0.861
BMI (kg/m2)
21.7 ± 2.2
26.9 ± 2.8
<0.001
ASA score
0.658
1
164 (65.9)
45 (71.4)
2
78 (31.3)
17 (27.0)
3
7 (2.8)
1 (1.6)
Distance from the anal verge (cm)
5.9 ± 2.1
5.9 ± 1.8
0.948
Gross type
0.843
Expanding
56 (22.5)
16 (25.4)
Ulcering
178 (71.5)
44 (69.8)
Infiltrating
15 (6.0)
3 (4.8)
Histopathology
0.100
Adenocarcinoma
227 (91.2)
53 (84.1)
Mucinous or signet ring adenocarcinoma
22 (8.8)
10 (15.9)
Tumor differentiation
0.196
Well or moderately differentiated
214 (85.9)
50 (79.4)
Poorly differentiated and othersa
35 (14.1)
13 (20.6)
Clinical T stage
0.230
T3
57 (22.9)
19 (30.2)
T4
192 (77.1)
44 (69.8)
Clinical N stage
0.580
N0
15 (6.0)
5 (7.9)
N+
234 (94.0)
58 (92.1)
Preoperative CEA level (ng/ml)
0.650
<5
216 (86.7)
56 (88.9)
≥5
33 (13.3)
7 (11.1)
Data are expressed as number (%) or as median ± standard deviation, where appropriate. aIncluding mucinous and signet cell carcinoma. nCRT: neoadjuvant chemoradiotherapy; BMI: body mass index; ASA: American Society of Anesthesiology; CEA: carcinoembryonic antigen.